Overview

Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Founded in 1977 by Gracias Saldanha, the company initially manufactured generic medicines and active pharmaceutical ingredients for India and selected international markets, including Russia and Africa. The Glenmark name combines the first names of Saldanha's sons, Glenn and Mark. The company became publicly traded in India in 1999 and subsequently developed a broad international presence. Its principal markets include India, North America, Europe, and a range of emerging markets. Glenmark manufactures and distributes medicines in more than 80 countries, supported by production and research operations in India, the United States, Argentina, and the Czech Republic. Its Indian manufacturing network includes facilities in Maharashtra, Himachal Pradesh, Goa, Madhya Pradesh, and Sikkim, while international production has included a site in Monroe, North Carolina, an oncology-injectables facility in Pilar, Argentina, and a Czech facility obtained through the acquisition of Medicamenta. Leadership by Glenn Saldanha, who became managing director in 2001 after experience at Eli Lilly and PricewaterhouseCoopers, marked an important phase of international expansion. Glenmark grew from a primarily generic-drug and ingredient manufacturer into a company with branded generics, specialty pharmaceuticals, consumer healthcare, and proprietary drug discovery. Its established portfolio includes respiratory, dermatology, cardiovascular, gastrointestinal, and anti-infective products. Brands such as Candid, Ascoril, La Shield, and Telma have been important in the Indian market. Telma, based on telmisartan, has been expanded into multiple formulations for cardiovascular care. During the mid-2010s, the company increased its emphasis on innovative and specialty medicines as the generic pharmaceutical sector faced fewer opportunities from major patent expirations. Glenmark developed internal candidates and entered licensing arrangements with larger pharmaceutical companies. Its research focus has included respiratory disease, oncology, dermatology, and diabetes. RYALTRIS, a combination nasal spray containing an antihistamine and corticosteroid, became one of its leading proprietary products after United States approval for seasonal allergic rhinitis and subsequent international commercialization. Glenmark's oncology strategy combines internal discovery with in-licensed medicines. Its portfolio and commercial relationships have included products from BeiGene, Jiangsu Alphamab, 3D Medicines, Hengrui Pharma, and Hansoh Pharma. In 2024, Glenmark and its subsidiary Ichnos Sciences created Ichnos Glenmark Innovation to consolidate oncology research and development. The organization was established around several clinical-stage molecules, including candidates with United States orphan-drug designations. In 2025, IGI entered a global licensing agreement with AbbVie for ISB 2001, a trispecific antibody being studied in relapsed or refractory multiple myeloma. Glenmark has also reorganized its portfolio and corporate structure. It sold a majority stake in Glenmark Life Sciences to Nirma Limited in 2024, separating the active-ingredient business from the pharmaceutical company. In 2025, its consumer healthcare products were transferred to Glenmark Consumer Care Limited. These steps reflected a continuing effort to focus the listed pharmaceutical business on branded generics, specialty medicines, and higher-value research programs while using separate structures for ingredients and consumer products.

History

Glenmark Pharmaceuticals was incorporated on 18 November 1977 by Gracias Saldanha. It began as a manufacturer of generic medicines and active pharmaceutical ingredients, supplying India and selected international markets. The company's name was formed from the names Glenn and Mark, Saldanha's sons. Glenmark listed its shares on India's Bombay Stock Exchange and National Stock Exchange in 1999. Glenn Saldanha became managing director in 2001. His tenure was associated with international expansion, wider manufacturing capacity, and a gradual move beyond commodity generics. By the late 2000s, Glenmark had become one of India's larger pharmaceutical manufacturers by sales volume. In 2011, it established a North American manufacturing presence through a facility in Monroe, North Carolina. The company also developed production capabilities in Argentina and the Czech Republic, in addition to its Indian network. The pharmaceutical market changed substantially during the 2010s as the number of attractive patent-expiry opportunities declined and price pressure increased in generic medicines. Glenmark responded by increasing investment in proprietary research and specialty products. Its research programs concentrated on areas including respiratory disease, oncology, dermatology, and diabetes. Rather than commercializing every candidate independently, the company used licensing arrangements with larger pharmaceutical groups to fund development and reach international markets. By 2016, several Glenmark-originated medicines were in clinical development, including a respiratory product licensed for North American and Japanese commercialization and a diabetes candidate licensed to Merck's German business. Glenmark simultaneously expanded its Indian branded-generics and consumer healthcare franchises. Candid, an antifungal brand launched in 1979, became a notable consumer healthcare product, alongside respiratory brand Ascoril and sunscreen and dermatology brand La Shield. Telma, a telmisartan-based cardiovascular brand launched in 2003, was extended into a range of related formulations. In March 2020, Glenmark sold its intimate-hygiene brand VWash to Hindustan Unilever. The company's proprietary respiratory strategy produced RYALTRIS, a nasal spray combining an antihistamine and corticosteroid. The product received United States approval for seasonal allergic rhinitis and was launched there in 2022. It subsequently became available in additional international markets. Glenmark also developed a broader specialty portfolio through licensing, including oncology products and treatments for other chronic conditions. Oncology became a central organizational priority in the 2020s. In January 2024, Glenmark and Ichnos Sciences established Ichnos Glenmark Innovation, bringing oncology discovery activities into a more focused platform. IGI's portfolio included clinical-stage molecules, with some receiving United States orphan-drug designations. In July 2025, IGI licensed ISB 2001 to AbbVie under a regional arrangement covering development and commercialization rights in major global markets while preserving Glenmark's rights in India and emerging markets. Glenmark also restructured its corporate portfolio. In 2024, it sold a 75 percent interest in Glenmark Life Sciences to Nirma Limited. In 2025, its consumer healthcare portfolio was transferred to Glenmark Consumer Care Limited. These transactions separated ingredients and consumer businesses from the listed pharmaceutical company's central branded-generics and specialty-medicine strategy. Manufacturing compliance has been a recurring operational issue. The Monroe facility was subject to a product recall in 2021 and an FDA warning letter in 2022 after deficiencies were identified. Glenmark has also received regulatory observations involving facilities in Himachal Pradesh, Goa, and Madhya Pradesh. The company has reported corrective actions, and a later inspection of the Monroe facility was classified as allowing manufacturing activity to resume. Glenmark therefore combines a large established generic and branded portfolio with a more research-oriented specialty strategy, while continuing to manage regulatory and manufacturing risks across its international network.

2025
ISB 2001 is licensed to AbbVie
[1]Glenmark Pharmaceuticalsen.wikipedia.org
IGI granted AbbVie regional rights to develop and commercialize the trispecific antibody ISB 2001.
2025
Consumer healthcare business is transferred to a subsidiary
[1]Glenmark Pharmaceuticalsen.wikipedia.org
Glenmark transferred its consumer healthcare products to Glenmark Consumer Care Limited.
2024
Ichnos Glenmark Innovation is formed
[1]Glenmark Pharmaceuticalsen.wikipedia.org
Glenmark and Ichnos Sciences created IGI to consolidate oncology discovery and development activities.
2024
Glenmark Life Sciences stake is sold to Nirma
[1]Glenmark Pharmaceuticalsen.wikipedia.org
Glenmark sold a majority stake in Glenmark Life Sciences to Nirma Limited.
2022
RYALTRIS launches in the United States
[1]Glenmark Pharmaceuticalsen.wikipedia.org
Glenmark launched RYALTRIS in the United States after approval for seasonal allergic rhinitis.
2020
VWash is sold to Hindustan Unilever
[1]Glenmark Pharmaceuticalsen.wikipedia.org
Glenmark divested its intimate-hygiene brand VWash to Hindustan Unilever.
2011
North American manufacturing expansion
[1]Glenmark Pharmaceuticalsen.wikipedia.org
Glenmark established its first North American manufacturing facility in Monroe, North Carolina.
2007
Glenmark acquires Czech manufacturing operations
[1]Glenmark Pharmaceuticalsen.wikipedia.org
The company acquired Medicamenta, adding a manufacturing facility in the Czech Republic.
2003
Telma cardiovascular brand is launched
[1]Glenmark Pharmaceuticalsen.wikipedia.org
Glenmark introduced Telma, a telmisartan-based brand for hypertension and cardiovascular care.
2001
Glenn Saldanha becomes managing director
[1]Glenmark Pharmaceuticalsen.wikipedia.org
Glenn Saldanha assumed the managing director role and led a period of international expansion and portfolio development.
1999
Glenmark becomes publicly listed in India
[1]Glenmark Pharmaceuticalsen.wikipedia.org
The company began trading on India's Bombay Stock Exchange and National Stock Exchange.
1983
First manufacturing plant opens in Maharashtra
[1]Glenmark Pharmaceuticalsen.wikipedia.org
Glenmark opened its oldest manufacturing site in Maharashtra, expanding its domestic production base.
1979
Candid consumer healthcare brand is launched
[1]Glenmark Pharmaceuticalsen.wikipedia.org
Glenmark introduced Candid, an antifungal consumer healthcare brand that became one of its established Indian-market products.
1977
Glenmark Pharmaceuticals is incorporated
[1]Glenmark Pharmaceuticalsen.wikipedia.org
Gracias Saldanha incorporated Glenmark on 18 November 1977 as a manufacturer of generic medicines and active pharmaceutical ingredients.

Products and positioning

Indian multinational pharmaceutical company positioned between branded generics and specialty pharmaceuticals, with additional activities in proprietary drug discovery, oncology licensing, respiratory care, dermatology, and consumer healthcare.

Respiratory medicine · 2022
RYALTRIS
RYALTRIS is a nasal spray combining an antihistamine with a corticosteroid for allergic rhinitis. It became a major proprietary product for Glenmark after United States approval for seasonal allergic rhinitis in adults and adolescents, followed by a United States launch in 2022 and expansion into additional international markets.
Consumer healthcare and dermatology · 1979
Candid
Candid is an antifungal brand introduced by Glenmark in 1979. It represents one of the company's long-standing Indian consumer healthcare franchises and is associated with topical treatment products for fungal skin conditions.
Respiratory medicine
Ascoril
Ascoril is a Glenmark respiratory brand sold in the Indian market. It forms part of the company's established branded portfolio in cough and respiratory care.
Cardiovascular medicine · 2003
Telma
Telma is a telmisartan-based cardiovascular brand launched in 2003 for hypertension. Glenmark has expanded it into multiple formulations, making it one of the company's important Indian branded-generic franchises.
Diabetes medicine · 2024
Lirafit
Lirafit is Glenmark's liraglutide biosimilar, launched in India in 2024 as part of the company's diabetes portfolio and its effort to broaden access to newer metabolic treatments.
Oncology medicine
QiNHAYO
QiNHAYO is Glenmark's brand for envafolimab in India and selected emerging markets. The product is marketed under a licensing relationship involving Jiangsu Alphamab and 3D Medicines.
Oncology pipeline
ISB 2001
ISB 2001 is a trispecific antibody being investigated for relapsed or refractory multiple myeloma. Ichnos Glenmark Innovation licensed regional development and commercialization rights to AbbVie while retaining rights in India and other emerging markets.

Controversies

2021
Recall of products manufactured at Monroe
Glenmark recalled products made at its Monroe, North Carolina facility after United States regulatory concerns about manufacturing practices. The episode was followed by further inspection findings and corrective-action work.
Source
2019
Glenmark recalls Estradiol Vaginal inserts in the United States
Glenmark Pharmaceuticals recalled approximately 217,000 cartons of Estradiol Vaginal inserts in the United States due to a defective delivery system. Complaints included that the applicator plunger was difficult to push. The FDA report described the action as a voluntary Class II recall.
Source

Brand decisions

2025
Global licensing of ISB 2001 to AbbVieM&A
Background
ISB 2001 was in early clinical development for relapsed or refractory multiple myeloma and required global development and commercialization resources.
Action taken
IGI granted AbbVie exclusive rights in North America, Europe, Japan, and Greater China, while retaining rights in India and other emerging markets.
Aftermath
The agreement gave AbbVie responsibility for major international territories and preserved Glenmark's participation in its home and selected emerging markets.
Upfront payment and potential milestones. USD 700 million upfront; up to USD 1.225 billion in potential milestones, plus tiered royalties (2025 licensing agreement)
Source
2025
Transfer of consumer healthcare products to Glenmark Consumer CareStrategy
Background
Glenmark continued to distinguish its consumer healthcare activities from its listed pharmaceutical operations.
Action taken
The company transferred its consumer healthcare products to Glenmark Consumer Care Limited.
Aftermath
Consumer healthcare became organized under a dedicated subsidiary while Glenmark Pharmaceuticals retained its core pharmaceutical and specialty focus.
Source
2024
Divestment of majority stake in Glenmark Life SciencesM&A
Background
Glenmark sought to separate its active pharmaceutical ingredient activities from its core pharmaceutical operations.
Action taken
The company sold a 75 percent stake in Glenmark Life Sciences to Nirma Limited.
Aftermath
The transaction reduced Glenmark's direct ownership of the life-sciences ingredients business and sharpened the distinction between the pharmaceutical company and its former subsidiary.
Transaction value. Approximately INR 56.51 billion (2024)
Source
2024
Creation of Ichnos Glenmark InnovationStrategy
Background
Glenmark aimed to focus and scale its oncology discovery programs through a dedicated innovation structure.
Action taken
Glenmark and Ichnos Sciences formed IGI and combined oncology discovery activities under the new organization.
Aftermath
IGI became the platform for advancing several clinical-stage oncology molecules and for subsequent licensing discussions with global pharmaceutical companies.
Source

Recent events

2022.01.20
Reported2022.01.20
Glenmark licenses Ryaltris commercialization to Lotus in Southeast Asian markets[4]Glenmark与Lotus签署Ryaltris东南亚市场许可协议freepressjournal.in
Glenmark Specialty S.A., a Swiss subsidiary of Glenmark Pharmaceuticals, entered into a licensing agreement with Lotus International for commercializing the Ryaltris nasal spray in Singapore, Hong Kong and Vietnam, subject to regulatory approvals. Glenmark will manufacture and supply the product, and Lotus will commercialize it.
Unconfirmed
Reported2022.01.14
FDA approves Ryaltris nasal spray[5]FDA批准Ryaltris鼻喷剂medscape.com
The US Food and Drug Administration approved Ryaltris, a prescription nasal spray for seasonal allergic rhinitis, for adults and pediatric patients aged 12 and older. It is manufactured by Glenmark Specialty SA, a subsidiary of Glenmark Pharmaceuticals.
2021.10.26
Reported2021.10.26
Glenmark launches two diabetes drug brands in India[6]Glenmark 在印度推出两款糖尿病药品品牌economictimes.indiatimes.com
Glenmark Pharmaceuticals said it launched a fixed-dose combination drug for diabetes in India under the brand names Remo MV and Remozen MV. The combination contains remogliflozin, vildagliptin and metformin.
2021.08.02
Reported2021.08.02
Glenmark and SaNOtize announce strategic partnership for nasal spray[7]Glenmark与SaNOtize宣布鼻喷剂战略合作business-standard.com
Glenmark Pharmaceuticals and SaNOtize Research & Development Corp. announced an exclusive long-term strategic partnership to manufacture, market and distribute the Nitric Oxide Nasal Spray for COVID-19 treatment in India and the named Asian markets.
2021.06.15
Reported2021.06.15
Glenmark launches Tiogiva in the UK[8]Glenmark在英国推出Tiogivahealth.economictimes.indiatimes.com
Glenmark Pharmaceuticals launched Tiogiva, a bioequivalent tiotropium bromide dry powder inhaler, in the UK for treatment of COPD.
2021.03.05
Reported2021.03.05
Glenmark signs Rohit Sharma as Candid Powder ambassador[9]Glenmark签约Rohit Sharma担任Candid Powder品牌大使equitybulls.com
Glenmark announced that Rohit Sharma had signed on to represent its Candid Powder brand as a brand ambassador.
2021.02.25
Reported2021.02.25
Glenmark receives India Pharma Innovation of the Year award[10]Glenmark获得“年度印度制药创新奖”equitybulls.com
Glenmark Pharmaceuticals received the “India Pharma Innovation of the Year” Award as part of the India Pharma & India Medical Device Awards 2021.
Unconfirmed
Reported2021.02.16
Glenmark launches SUTIB in India[11]Glenmark在印度推出SUTIBbusiness-standard.com
Glenmark launched SUTIB, a generic version of Sunitinib oral capsules for treating kidney cancer, in India.
2020.12.29
Reported2020.12.30
Glenmark launches Remo V and Remozen V in India[12]Glenmark在印度推出Remo V和Remozen Vtimesnownews.com
Glenmark Pharmaceuticals launched fixed-dose Remogliflozin Etabonate and Vildagliptin products under the brand names Remo V and Remozen V in India for the management of Type 2 diabetes.
2020.11.30
Reported2020.11.30
Dr. Reddy's agrees to acquire selected Glenmark brands[13]Dr. Reddy's同意收购Glenmark部分品牌business-standard.com
Dr. Reddy's Laboratories announced a definitive agreement to acquire selected anti-allergy brands and associated intellectual property rights from Glenmark Pharmaceuticals for specified territories, subject to precedent actions and closing activities.